Our mission is to empower
people with hemophilia to live
the lives they choose.

Our goal is to transform hemophilia management
by researching long-lasting, fully recombinant
clotting factors.

In a word, Biogen Idec Hemophilia is dedicated. We're dedicated to improving the lives of people with hemophilia and dedicated to the community in which our team is so deeply rooted.

For our team members our commitment is personal; many of us have devoted our careers to advancing hemophilia care. We bring years of experience from many different sectors of the community: factor manufacturers, advocacy organizations, and hemophilia treatment centers, to name just a few.

Our parent company, Biogen Idec, has been developing innovative therapies for people with chronic conditions for more than 30 years. Biogen Idec Hemophilia has combined this long-standing tradition of excellence with a team deeply rooted in the hemophilia community to develop our next innovation—long-lasting clotting factors.

Our vision for the future of hemophilia treatment has attracted a number of leaders from the hemophilia community, such as Glenn Pierce, MD, PhD, former President of the National Hemophilia Foundation. Dr Pierce is the Chief Medical Officer for Biogen Idec Hemophilia and Senior Vice President of Global Medical Affairs for all of Biogen Idec.